OBJECTIVE: The objective of the study is to evaluate bone repair in rats treated with different alendronate doses. MATHERIALS AND METHODS: Sixty female rats ovariectomized were randomly divided in three groups: group C (control group), group A1 (ALN/1 mg/kg), and A2 (ALN/ 3 mg/kg). Each animal received subcutaneous applications of sodium alendronate at a dose correspondent to group A1 or A2 three times a week, while the control group received 0.9% saline solution. After 4 weeks of application, a critical defect was created in the calvaria of animals of all groups. The defect was filled by particulate autogenous bone. The applications were maintained until euthanasia, which occurred 15 and 60 days after the surgical procedure. The pieces were sent for histological, histomorphometric and immunohistochemical analysis. The data were submitted to statistical analysis with significance level of 0.05. RESULTS: The descriptive histological analysis demonstrated an increase in bone neoformation in both groups treated with alendronate when compared to the control group. The histomorphometric analysis showed an increase in the amount of neoformed bone in A1 and A2 groups when compared to group C, both at 15 days (p = 0.0002) and at 60 days (p = 0.001). In the immunohistochemical analysis, it was possible to observe a difference in immunolabeling just for Mmp2 at the time of 60 days in A1 (p = 0.001) and A2 (p = 0.023) when compared to the control group. CONCLUSION: Systemic delivery of alendronate, regardless of the dose, increased the amount of bone neoformation. CLINICAL RELEVANCE: Prescription of sodium alendronate at 1 mg/kg for improvement of bone neoformation in bone graft procedures.
OBJECTIVE: The objective of the study is to evaluate bone repair in rats treated with different alendronate doses. MATHERIALS AND METHODS: Sixty female rats ovariectomized were randomly divided in three groups: group C (control group), group A1 (ALN/1 mg/kg), and A2 (ALN/ 3 mg/kg). Each animal received subcutaneous applications of sodium alendronate at a dose correspondent to group A1 or A2 three times a week, while the control group received 0.9% saline solution. After 4 weeks of application, a critical defect was created in the calvaria of animals of all groups. The defect was filled by particulate autogenous bone. The applications were maintained until euthanasia, which occurred 15 and 60 days after the surgical procedure. The pieces were sent for histological, histomorphometric and immunohistochemical analysis. The data were submitted to statistical analysis with significance level of 0.05. RESULTS: The descriptive histological analysis demonstrated an increase in bone neoformation in both groups treated with alendronate when compared to the control group. The histomorphometric analysis showed an increase in the amount of neoformed bone in A1 and A2 groups when compared to group C, both at 15 days (p = 0.0002) and at 60 days (p = 0.001). In the immunohistochemical analysis, it was possible to observe a difference in immunolabeling just for Mmp2 at the time of 60 days in A1 (p = 0.001) and A2 (p = 0.023) when compared to the control group. CONCLUSION: Systemic delivery of alendronate, regardless of the dose, increased the amount of bone neoformation. CLINICAL RELEVANCE: Prescription of sodium alendronate at 1 mg/kg for improvement of bone neoformation in bone graft procedures.
Entities:
Keywords:
Alendronate; Bone regeneration; Matrix metalloproteinase 2; Wnt3a protein
Authors: Qing Luo; Quan Kang; Weike Si; Wei Jiang; Jong Kyung Park; Ying Peng; Xinmin Li; Hue H Luu; Jeffrey Luo; Anthony G Montag; Rex C Haydon; Tong-Chuan He Journal: J Biol Chem Date: 2004-10-20 Impact factor: 5.157
Authors: Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Luana Mordask Bonetto; Paola Fernanda Cotait de Lucas Corso; Gabrielle Grosko Kuchar; Jennifer Tsi Gerber; Leonardo Fernandes Cunha; Mohammed Elsalanty; João Cesar Zielak; Carla Castiglia Gonzaga; Rafaela Scariot Journal: Front Cell Dev Biol Date: 2021-05-05